|Day Low/High||97.24 / 98.56|
|52 Wk Low/High||77.00 / 96.57|
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
Santa is on his way... A lot of pressure on the jolly fellow this year.
Straying from these names could land you in quicksand as the 4th quarter begins.
ZTS discovers, develops, manufactures, and markets veterinary vaccines and medicines.
Let's take the charts and indicators for a walk and see how high they may go in the weeks ahead.
The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.
Go long on strong fundamentals, or try this options strategy.
Consistency in discipline will make the difference.
Overreaction seems to be what markets are good at in this 'golden age of electronic trading.'
A partial list of names that are showing signs of breaking out Monday.
My economist side would clearly prefer a rules-based approach toward monetary policy.
The list begins with oil, but there's a ripple effect.
The company lowered guidance for FY 2017, which is likely to blame for the company's fall.
Ackman launched a winning activist campaign at Chipotle last year.
The Mars-VCA deal is yet another sign that pet health is a robust business.
Zoetis shares were climbing off an earnings beat and raised 2016 guidance.
Jim Cramer says Zoetis, an animal health company, is well run.
Teeth, pets, video games, eating at home are evidence of strong theses.
Here's a window into what institutional investors may be doing and how to profit from that.
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
Zoetis is not averse to a little noise as investors, analysts take notice.
Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.